HCRI BioBank
Oncology Biospecimens for Translational and Precision Cancer Research
About HCRI BioBank
The HCRI Biobank is a centralized oncology research infrastructure supporting translational and precision cancer research through access to high-quality human biospecimens integrated with rich clinical and pathological data.
Designed to bridge clinical care and discovery science, the HCRI Biobank enables biomarker discovery, therapy development, and data-driven oncology research by providing ethically sourced, well-annotated biospecimens that reflect real-world clinical complexity.
Therapeutic Area: Oncology
Advances in cancer research increasingly depend on access to biospecimens that capture tumor biology, disease heterogeneity, and treatment response over time.
The HCRI Biobank supports a broad range of oncology research programs across solid tumors and hematologic malignancies, enabling studies from early discovery to late-stage translational validation.
Translational cancer research
Precision medicine initiatives
Immuno-oncology and cell-based therapy development
Diagnostic, prognostic, and predictive biomarker validation
Cancer Diagnoses Covered
The HCRI Biobank supports research across a wide spectrum of cancer indications, reflecting diverse disease types, stages, and clinical trajectories.
Solid Tumors
- Breast cancer
- Colorectal cancer
- Lung cancer (NSCLC and SCLC)
- Head and Neck squamous cell carcinoma (SCC)
- Liver cancer
- Pancreatic cancer
- Kidney cancer
- Bladder cancer
- Prostate cancer
- Melanoma
- Brain tumors
Hematologic Malignancies
- Lymphoma (Hodgkin and Non-Hodgkin)
- Leukemia
Additional cancer indications may be supported upon request, subject to availability and study design.
Further indications on request
Available Biospecimen Types
The HCRI Biobank provides access to a diverse range of high-quality biospecimens collected and processed under standardized operating procedures to ensure consistency, traceability, and scientific validity.
Available specimen types include:
- Serum
- Plasma
- Whole blood
- Peripheral Blood Mononuclear Cells (PBMCs)
- FFPE tumor tissue
- Dissociated tumor samples
- Urine
- Saliva
Hematologic Malignancies
- Lymphoma (Hodgkin and Non-Hodgkin)
- Leukemia
Additional cancer indications may be supported upon request, subject to availability and study design.
Further indications on request
Clinical and Pathological Annotation
Each biospecimen is accompanied by structured clinical and pathological metadata, enhancing its scientific value and enabling meaningful data interpretation.
Annotations may include:
Diagnosis and tumor classification
Disease stage and grade
Treatment history and therapeutic exposure
Clinical outcomes and follow-up data
Demographic and comorbidity information
Guy Gross
Operations Manager
Hadassah Biobank | MIDGAM